Swastik Pharmaceuticals Ltd Pharmaceutical Import Profile — Uganda (DGFT 2022–2026)

Name: Swastik Pharmaceuticals Ltd Pharmaceutical Import Records from India — 2 Products, $464.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Swastik Pharmaceuticals Ltd — Pharmaceutical Importer Profile (2026) | 2 Products, $464.5K Trade | TransData Nexus

Swastik Pharmaceuticals Ltd

Pharmaceutical Importer · Uganda · Advanced Antibiotics Focus · $464.5K Total Trade · DGFT Verified

Swastik Pharmaceuticals Ltd is a pharmaceutical importer based in Uganda with a total trade value of $464.5K across 2 products in 1 therapeutic categories. Based on 16 verified import shipments from Indian Customs (DGFT) records, Swastik Pharmaceuticals Ltd is the #1 buyer in 1 product including Gatifloxacin. Swastik Pharmaceuticals Ltd sources from 5 verified Indian suppliers, with Aurolab Trust accounting for 92.6% of imports.

Swastik Pharmaceuticals Ltd — Import Portfolio & Supplier Network

Swastik Pharmaceuticals Ltd import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Swastik Pharmaceuticals Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurolab Trust	$1.7M	181	92.6%
Twentyfirst Century Pharmaceuticals Private Limite	$76.7K	16	4.3%
Aurolab Foundation	$42.3K	28

What Formulations Does Swastik Pharmaceuticals Ltd Import?

Formulation	Value	Ships
Polycryl [8/0 poly glycolic acid	$202.8K	6
Aurolon [9/0 nylon black monofilament	$202.6K	7
Aurofort [prednisolone acetate 1% -	$121.3K	7
Aurotim[timolol maleate 0.5% w/v - 5	$106.6K	7
Gflox[gatifloxacin 0.3% w/v -	$104.5K	6
Atrop [atropine sulphate 1% w/v -	$102.7K	6
Auroprost - rt[latanoprost 0.005% w/v-2.	$102.0K	3
Mflox -dm [moxifloxacin 0.5% w/v with	$101.5K	3
Aurovisc[hydroxypropyl methylcellulose	$101.0K	3
Aurocaine[proparacaine hydrochloride	$82.2K	8
Ketolac [ketoraloc tromethamine 0.5%	$63.3K	6
Aurocol [chloramphenicol 0.5% w/v - 10	$60.2K	5
Aurosporine [cyclosporine 2% w/v -	$52.0K	5
Auromide plus [tropicamide 0.8% w/v	$48.6K	5
Auropent [cyclopentolate hcl 1% w/v -	$41.5K	4

Swastik Pharmaceuticals Ltd imports 134 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Moxifloxacin	Advanced Antibiotics	$257.8K	10	0.8%	18
2	Gatifloxacin	Advanced Antibiotics	$206.7K	6	25.8%	1

Swastik Pharmaceuticals Ltd imports 2 pharmaceutical products across 1 categories into Uganda totaling $464.5K. The company is the #1 buyer for 1 product: Gatifloxacin.

Swastik Pharmaceuticals Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Swastik Pharmaceuticals Ltd is a pharmaceutical importer and distributor based in Kampala, Uganda. The company operates as a wholesaler, sourcing a range of pharmaceutical products from international suppliers, particularly from India. Its primary focus is on importing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, to meet the healthcare needs within Uganda. The company's headquarters are located at Galiraaya Commercial Plaza, William Street, Kampala.

In Uganda's pharmaceutical distribution landscape, Swastik Pharmaceuticals Ltd plays a pivotal role as a key wholesaler. By importing a diverse array of pharmaceutical products, the company ensures a steady supply of essential medications to various healthcare facilities, pharmacies, and clinics across the country. This distribution network is crucial for maintaining the availability of both generic and branded medicines, thereby supporting the overall healthcare infrastructure in Uganda.

2Distribution Network

Swastik Pharmaceuticals Ltd's distribution network is centered in Kampala, with its main office situated at Galiraaya Commercial Plaza, William Street. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Kampala suggests a focus on efficient distribution within the capital and surrounding regions. This central location likely facilitates timely deliveries to various healthcare providers and retailers across Uganda.

The company's logistics operations are designed to handle the importation and distribution of pharmaceutical products, ensuring compliance with Uganda's regulatory standards. Given the critical nature of pharmaceutical supply chains, Swastik Pharmaceuticals Ltd is expected to maintain robust logistics capabilities to manage inventory, coordinate shipments, and ensure the safe delivery of products to meet the demands of the Ugandan market.

3Industry Role

In Uganda's pharmaceutical supply chain, Swastik Pharmaceuticals Ltd functions primarily as a wholesaler. The company imports finished pharmaceutical formulations from international suppliers, particularly from India, and distributes these products to various stakeholders within the healthcare sector. By serving as an intermediary between international manufacturers and local healthcare providers, Swastik Pharmaceuticals Ltd plays a crucial role in ensuring the availability of a wide range of pharmaceutical products in Uganda.

The company's position as a wholesaler enables it to influence the pharmaceutical market by selecting and introducing products that meet the specific needs of the Ugandan population. This role is vital for maintaining a diverse and accessible pharmaceutical market, which is essential for addressing the healthcare challenges faced by the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Swastik Pharmaceuticals Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Swastik Pharmaceuticals Ltd exhibits a high degree of sourcing concentration, with a significant portion of its imports originating from a single supplier, AUROLAB TRUST. Between 2022 and 2026, AUROLAB TRUST accounted for approximately 92.6% of the company's total shipments, amounting to $1.7 million across 181 shipments. This substantial reliance indicates a strategic partnership between Swastik Pharmaceuticals Ltd and AUROLAB TRUST, likely due to favorable terms, product quality, and reliability.

However, such a concentrated sourcing strategy also presents potential risks. Any disruptions in AUROLAB TRUST's operations—such as production delays, quality control issues, or logistical challenges—could directly impact Swastik Pharmaceuticals Ltd's ability to meet market demand. To mitigate these risks, it would be prudent for Swastik Pharmaceuticals Ltd to diversify its supplier base, ensuring a more resilient supply chain capable of withstanding unforeseen disruptions.

2Supply Chain Resilience

Swastik Pharmaceuticals Ltd's supply chain resilience is closely tied to its sourcing strategy. The company's heavy reliance on AUROLAB TRUST for the majority of its imports suggests a streamlined and efficient supply chain. However, this concentration also means that the supply chain is vulnerable to any disruptions affecting AUROLAB TRUST.

Importing Pharmaceuticals into Uganda — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Uganda

1Regulatory Authority & Framework

In Uganda, the National Drug Authority (NDA) is the primary regulatory body responsible for overseeing the manufacture, importation, distribution, and sale of pharmaceutical products. Established by the National Drug Policy and Authority Act (Cap 206), the NDA ensures that all drugs available in the Ugandan market meet the required standards of quality, safety, and efficacy. (nda.or.ug)

The NDA operates under a comprehensive legal framework that includes the National Drug Policy and Authority Act and associated regulations. This framework outlines the procedures for drug registration, importation, exportation, and the licensing of pharmaceutical entities. The NDA's mandate encompasses the regulation of all drugs, including human, veterinary, and medical devices, ensuring that they are safe for use and effective for their intended purposes. (nda.or.ug)

2Import Licensing & GMP

To import pharmaceutical products into Uganda, entities must obtain a valid import license from the National Drug Authority (NDA). This license is typically issued for a period of one year and specifies the range of preparations that the licensee is authorized to import during that period. Additionally, importers are required to apply for a Verification Certificate for each consignment of drugs prior to importation, ensuring that the products meet the necessary standards and are authorized for entry into the country. (nda.or.ug)

Swastik Pharmaceuticals Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Swastik Pharmaceuticals Ltd's focus on importing advanced antibiotics, particularly moxifloxacin and gatifloxacin, indicates a strategic alignment with the therapeutic needs of the Ugandan market. The substantial import values of these products—$258K for moxifloxacin and $207K for gatifloxacin—suggest a significant demand for these medications within the country. This demand may be driven by the prevalence of bacterial infections and the need for effective treatment options.

By concentrating on these specific therapeutic areas, Swastik Pharmaceuticals Ltd aims to address critical healthcare challenges in Uganda. The company's import strategy reflects an understanding of the local market dynamics and a commitment to providing essential medications that meet the needs of healthcare providers and patients.

2Sourcing Profile

Swastik Pharmaceuticals Ltd's sourcing strategy is heavily centered on importing finished pharmaceutical formulations from India, with a particular emphasis on advanced antibiotics. This focus aligns with the company's goal of supplying high-quality, effective medications to the Ugandan market. The choice of India as a primary sourcing

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Swastik Pharmaceuticals Ltd

What products does Swastik Pharmaceuticals Ltd import from India?

Swastik Pharmaceuticals Ltd imports 2 pharmaceutical products across 1 categories. Top imports: Moxifloxacin ($257.8K), Gatifloxacin ($206.7K).

Who supplies pharmaceuticals to Swastik Pharmaceuticals Ltd from India?

Swastik Pharmaceuticals Ltd sources from 5 verified Indian suppliers. The primary supplier is Aurolab Trust (92.6% of imports, $1.7M).

What is Swastik Pharmaceuticals Ltd's total pharmaceutical import value?

Swastik Pharmaceuticals Ltd's total pharmaceutical import value from India is $464.5K, based on 16 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Swastik Pharmaceuticals Ltd focus on?

Swastik Pharmaceuticals Ltd imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full Swastik Pharmaceuticals Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.